InvestorsHub Logo
Followers 23
Posts 1725
Boards Moderated 0
Alias Born 09/03/2015

Re: steadyhand post# 16650

Thursday, 02/22/2018 11:20:41 AM

Thursday, February 22, 2018 11:20:41 AM

Post# of 21373
I don't see why the Asian licensing partner wouldn't happen? Prolanta has serious potential given the science and research supporting it. Why wouldn't another company want a piece of a potential breakthrough cancer treatment?

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.